Â鶹Æƽâ°æ

Management

Â鶹Æƽâ°æ’s team is world class with a crucial mix of pharma senior leadership who proved their scientific excellence and financiers with deep understanding of pharma business.

Dr Jacky Vonderscher, PhD, co-founder and Chief Executive Officer

• Founder of Vonderscher&Co GmbH
• Senior executive with a broad R&D experience in the pharmaceutical industry
• Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
• Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
• Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
• Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
• Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
• Board member of Inatherys, Step Pharma and ObsEva and SAB member of Inotrem SA
• Board member of LyonBiopôle and IMI-JU (Innovative Medicines Initiative-Joint Undertaking)

Dr Pietro Scalfaro, MD, MBA, SVP Head of Clinical Development Chief Medical Officer

• In charge of strategy and operational management of the clinical programs
• Wide range experience in various roles in the healthcare sector, working notably in infectious diseases (HCV, via the development of Alisporivir), sepsis, oncology, Alzheimer’s disease and cardio-respiratory diseases
• Set up the Personalised Medicine Business Unit at Debiopharm Group and involved during start-up of eHealth and diagnostic companies: Biocartis, Sophia Genetics, Agendia, Immunexpress, Pryv, Orphanalytics
• Practicing physician, with degrees in Paediatrics, Intensive Care Medicine and an MBA from the University of Lausanne and the Swiss Medical Association.

Dr Raphaël Darteil, PhD, SVP Head of non-clinical Development & Profiling

• Responsible for non-clinical development and in vitro / in vivo compound profiling
• More than 20 years of experience in R&D project and portfolio management in the Pharma and Biotech industries
• Scientific expertise in metabolic diseases (including NAFLD/NASH) and in the Nuclear Receptor field
• COO and Member of the board at Genfit
• Various positions in the department of Gene Therapy of Aventis both in France and in the US
• Co-inventor of the patent protecting the use of Elafibranor (Phase III) for the treatment of NASH patients
• He owns a PhD in Molecular and Cellular Biology from the University Claude Bernard Lyon I

Keltoum Medji, MBA, VP Finance and Strategic Development

• Responsible for all finance activities including fundraising, investors relations, strategic partnerships
• More than 20 years’ experience in Orthopedic business supporting growth by an increased collaboration with supply chain & commercial organizations
• Strong experience in change management through diverse organizational changes as M&A, restructuring, reorganizations
• Graduated with a Master’s degree in Economics & Business Management and an MBA from EM Lyon Business School

Claudi Miquel, VP Legal Affairs & Board Secretary

• Responsible for all legal affairs and Secretary of the Board of Directors
• 15 years’ experience as an attorney as well as lead counsel for international organizations across different jurisdictions
• Experience in transactional, financing, IP, and corporate/governance matters
• Graduated with a master’s degree in business law from Vanderbilt University law school

Pete Leone, MBA, Head of Business Development & Licensing

• Responsible for Business development
• More than 30 years of C-level experience at public and private biopharmaceutical companies, with over $6 billion in upfront payments and potential milestones from business development transactions that he led to closure
• Various management roles at Arrowhead Pharmaceuticals (Nasdaq: ARWR), including business development, was CBO at Bicycle Therapeutics (Nasdaq: BCYC), and previously, a cofounder of three venture-backed companies, including Mersana Therapeutics (Nasdaq: MRSN)
• Corporate and not-for-profit board member, including SeromYx Systems, Third Monday Foundation, and Nuestros Pequeños Hermanos – NPH USA Northeast region
• Holds an A.B. in engineering science with pre-med studies from Dartmouth College and an MBA from the Stanford University Graduate School of Business

History of Â鶹Æƽâ°æ with virus biomimetism

Our story began in 2014 when experts in virus-host protein interactions from the French Infectiology Research Center (Inserm) in Lyon, France and pharmaceutical industry executives specialized in drug development developed a unique drug discovery platform based on biomimetism inspired by viruses.

Founders

Jacky Vonderscher, PhD, CEO: see above

Laurène Meyniel-Schicklin, Engineer: Head of Bioinformatics, 15 years experience in omics data management and analysis for drug discovery Team and project leader, responsible for bioinformatics, scientific data management and analysis ; Engineer in Biology and Computer Science (Genopole, Evry)

Benoît de Chassey, PhD: Head of Drug Discovery Platform, 18 years experience in high-throughput approaches in drug discovery ; Former project leader in functional screenings at Aptanomics

Patrice André, MD, PhD: Medical Advisor, Professor Emeritus of Virology at Charles Mérieux Lyon Sud Medical School, Lyon 1 University; Former Head of clinical virology department at the Hospices Civils de Lyon; Former Team leader at the International Center for Infectiology Research, Inserm, CNRS, ENS Lyon

Vincent Lotteau, PhD: Advisor, Inserm Research Director, Immunologist ; Team leader at the International Center for Infectiology Research; Former director of Inserm Unit « Fundamental and clinical immunology »; Participated to several French governmental missions

Jean-Jacques Garaud, MD: Co-founder and CEO of Inotrem SA (2013-2021); Executive vice-president Medical and Scientific Affairs, Inotrem SA; A senior executive with a broad R&D experience in the pharmaceutical industry; Executive VP Head of Pharma Research and Early Development at Roche; Executive VP Head of Development and CMO at Roche ; Previously held other senior positions with Shering-Plough in the USA and with Novartis in the USA and Switzerland

Inserm Transfert Initiative: Created in 2005, Inserm Transfert Initiative is a seed-capital company with € 39.7 M capital, further to its second fund raising in 2012; It focuses on providing seed capital for innovative young companies in the biomedical field. Inserm Transfert Initiative supports biotech entrepreneurs in the early stages of their companies’ development.